Drug-Induced Uveitis: Causes, Symptoms, and Treatment
Understanding Drug-Induced Uveitis
Uveitis is inflammation of the uvea, the middle layer of the eye that contains most of the eye's blood vessels. This inflammation can damage eye tissue and affect vision. Uveitis has many possible causes, including infections, autoimmune diseases, and reactions to medications.
When a medication triggers this inflammation, it is called drug-induced uveitis. The inflammation can occur in different parts of the eye. It may appear as anterior uveitis (in the front of the eye), intermediate uveitis (in the middle), or posterior uveitis (in the back near the retina). It can also present as panuveitis, which affects all layers.
The exact way medications trigger uveitis is not fully understood. Researchers have identified two main categories of mechanisms: direct and indirect.
- Direct mechanisms occur when a drug reaches the inside of the eye through eye drops, injections, or surgery. The drug itself, a byproduct, or even inactive ingredients may have a toxic effect on eye tissue. This can break down the blood-ocular barrier that normally protects the inside of the eye.
- Indirect mechanisms occur when medications taken by mouth or through an IV trigger an immune response. The drug may cause antibodies that deposit in the uveal tissue, activating the immune system. This releases inflammatory chemicals such as TNF-alpha and IL-6.
- Some drugs bind to melanin, a pigment found in the eye. This binding may trigger inflammation and reduce melanin's ability to neutralize harmful molecules called free radicals.
- Certain antibiotics can kill microorganisms rapidly. This releases antigens that provoke an immune reaction in the eye.
Drug-induced uveitis is rare. It accounts for less than 0.5% of uveitis cases seen at major referral centers (NIH, StatPearls). However, the true number may be higher because many cases go unreported or unrecognized. Not every person who takes a medication associated with uveitis will develop eye inflammation. Individual risk varies based on genetics, dosage, and other factors.
Who Is Affected and Risk Factors
Anyone taking a medication linked to uveitis could potentially develop eye inflammation. However, certain factors may increase the risk. Higher doses, lower body weight, and taking multiple drugs at the same time can all raise the likelihood of a reaction.
Genetic factors also play a role. Among patients with fluoroquinolone-induced uveitis, the HLA-B27 marker was found in 20% of tested individuals. The HLA-B51 marker was found in 40% (PMC, 2021). These genetic markers are associated with a higher tendency toward inflammatory conditions.
Drug-induced uveitis appears to affect women more often than men in certain medication categories. In a review of 40 cases of fluoroquinolone-induced uveitis, 69% of patients were women. The median age was 54 years (PMC, 2021). These patterns may reflect differences in how certain drugs are processed in the body.
Some medications show different rates of drug-induced uveitis among racial groups. For corticosteroid-related uveitis, the incidence in Black patients is a moderate percentage compared to a very small percentage in white patients (NIH, StatPearls, 2024). The reasons for this difference are not entirely clear. They may relate to variations in melanin content and drug-melanin interactions within the eye.
Certain medications carry well-documented risks. The antiviral drug cidofovir causes nongranulomatous anterior uveitis in 70% to 89% of cases (AAO). It also causes low eye pressure (hypotony) in approximately 10% of cases. Risk is higher in patients also taking protease inhibitors. For rifabutin, risk factors include doses of 600 mg or more per day, low body weight, and use of macrolide antibiotics or ritonavir at the same time.
Signs and Symptoms
Drug-induced uveitis shares symptoms with other forms of uveitis. The most common symptoms include eye pain, sensitivity to light (photophobia), blurred vision, and redness. These symptoms may develop in one or both eyes.
The severity of symptoms can range from mild discomfort to significant vision changes. Some patients notice only slight blurriness, while others experience intense pain and marked vision loss.
The time between starting a medication and developing symptoms varies widely. It can range from a few days to several months. The route of administration affects how quickly symptoms appear. Intravenous medications may cause symptoms as early as 6 hours after administration. Oral medications may take several days or longer to trigger a reaction.
In cases of fluoroquinolone-induced uveitis, the average time to developing symptoms is about 13 days. The range is 0 to 20 days (PMC, 2021).
Some medications produce characteristic patterns that help retina specialists identify the cause. Fluoroquinolone-induced uveitis has three signature findings.
- Pigment dispersion with pigmented deposits on the inner surface of the cornea (keratic precipitates), along with elevated eye pressure
- Widespread iris transillumination defects, meaning light passes through areas of the iris that have lost pigment
- Atonic pupils, meaning the pupils respond poorly to light
These patterns can help distinguish drug-induced uveitis from other causes of eye inflammation.
Diagnosis and Testing
Diagnosing drug-induced uveitis is difficult because no single laboratory test can confirm it. A retina specialist must rely on clinical judgment, patient history, and the process of elimination. The timing of symptom onset relative to starting a new medication is one of the most important clues.
Making the diagnosis harder is the fact that individual responses vary greatly. A drug known to cause uveitis in some patients may not cause the same reaction in others.
A retina specialist will perform a thorough eye examination using a slit lamp (a microscope with a bright light). They will look for signs of inflammation inside the eye. This includes checking for cells and protein in the fluid at the front of the eye, examining the iris for damage, and measuring eye pressure.
For posterior or panuveitis, additional imaging may be needed. OCT (optical coherence tomography, a scan that creates detailed cross-section images of the retina) can help assess inflammation. Fluorescein angiography, a test that uses dye to photograph blood vessels in the retina, may also be used.
A detailed review of all current and recent medications is essential. The specialist will look for a temporal relationship between starting a new drug and the onset of symptoms. They will also consider whether the medication is on the known list of drugs associated with uveitis.
Other potential causes of uveitis must be ruled out through blood tests and other evaluations. These include infections and autoimmune diseases. A drug-induced cause can be confirmed only after other possibilities are excluded.
Treatment Options
The most important step in treating drug-induced uveitis is identifying and discontinuing the medication causing the reaction. In many cases, this alone leads to resolution of the inflammation. If the offending drug is essential for treating another condition, a retina specialist will work with the prescribing physician to find an alternative.
Drug-induced uveitis typically resolves within weeks after the responsible medication is stopped. However, some cases may take longer, depending on severity and the specific drug involved.
For anterior uveitis caused by medications, intensive topical corticosteroid eye drops are the standard treatment. These drops reduce inflammation inside the eye and help prevent complications. Cycloplegic or mydriatic eye drops (medications that dilate the pupil and relax the focusing muscle) are often prescribed alongside steroids. These reduce pain and prevent the iris from sticking to the lens.
The frequency of steroid eye drops depends on the severity of inflammation. A retina specialist will create a tapering schedule, gradually reducing the drops as inflammation improves.
When inflammation is severe, involves the back of the eye, or does not respond to topical treatment, systemic corticosteroids may be needed. These are taken by mouth or by injection. In rare cases where inflammation persists despite stopping the offending drug and using steroids, additional anti-inflammatory medications may be considered.
The goal of treatment is to control inflammation quickly. This helps prevent serious damage to eye structures, including the retina.
Some forms of drug-induced uveitis cause elevated eye pressure, while others cause abnormally low pressure (hypotony). Both conditions can harm vision. A retina specialist will monitor eye pressure closely during treatment and may prescribe pressure-lowering eye drops if needed.
What to Expect
Most patients with drug-induced uveitis recover well once the offending medication is identified and stopped. Mild cases may resolve within one to two weeks. More severe cases can take several weeks to months for the inflammation to fully clear.
Vision typically improves as inflammation decreases. However, recovery depends on how much damage occurred before treatment began. Early detection and prompt treatment lead to the best outcomes.
Regular follow-up visits with a retina specialist are important during recovery. These visits allow the specialist to monitor inflammation levels, check for complications, and adjust treatment as needed. Even after the inflammation appears to resolve, one or two additional visits may be recommended to confirm it does not return.
If drug-induced uveitis is not recognized and treated promptly, it can lead to complications. These may include elevated eye pressure or glaucoma, cataract formation, and macular edema (swelling in the central retina). In severe cases, significant and lasting vision loss may occur. Fortunately, with timely treatment, most patients avoid serious long-term effects.
Living With Drug-Induced Uveitis
If you have experienced drug-induced uveitis, it is important to inform all of your healthcare providers about this reaction. Keep a record of the specific medication that caused the problem. This information helps prevent future exposure to the same drug or closely related medications.
Before starting any new medication, mention your history of drug-induced uveitis. Your healthcare providers can consider alternative treatments. They can also monitor you more closely if a potentially problematic drug is necessary.
A wide range of medications has been linked to uveitis. Being aware of the categories can help you stay alert for symptoms.
- Topical eye medications: prostaglandin analogs (used for glaucoma), metipranolol, brimonidine, certain corticosteroid preparations, and cholinomimetic drugs
- Systemic medications: fluoroquinolone antibiotics (especially moxifloxacin), rifabutin, bisphosphonates, sulfonamides, and certain diuretics
- Anticancer immunotherapies: immune checkpoint inhibitors, BRAF inhibitors, and MEK inhibitors. Approximately 41.1% of patients on cancer immunotherapy for malignant melanoma develop ocular side effects (AAO)
- Intravitreal medications: cidofovir, certain antibiotics, and biologic agents such as ranibizumab and Avastin (bevacizumab), which is used off-label for eye conditions
- Vaccines: various vaccines have been associated with rare cases of uveitis
The long-term outlook for drug-induced uveitis is generally favorable. Once the offending drug is removed and the inflammation is treated, most patients do not experience recurrence. The key is avoiding future exposure to the same medication. In most cases, there is no underlying tendency toward uveitis. The condition does not return unless triggered again by a similar drug.
When to See a Retina Specialist
Seek care from a retina specialist or go to the emergency room immediately if you experience sudden vision loss, a significant increase in floaters, flashes of light, or a shadow or curtain across your vision. These symptoms may indicate serious complications that require urgent evaluation.
Eye pain, redness, and sensitivity to light that develop after starting a new medication should also be evaluated promptly by a retina specialist.
If you are taking a medication known to be associated with uveitis, discuss the need for periodic eye examinations with your retina specialist. Patients on long-term therapy with high-risk medications may benefit from scheduled monitoring even before symptoms develop. This includes those on cancer immunotherapies or cidofovir. Early detection of subclinical inflammation can prevent more serious problems.
Questions and Answers
Most reported cases of drug-induced uveitis involve prescription medications. However, some over-the-counter supplements and medications have been linked to rare cases of eye inflammation. If you develop eye pain, redness, or blurred vision after starting any new product, including supplements, report it to a retina specialist for evaluation.
In the vast majority of cases, treatment with eye drops is temporary. Once the offending medication is stopped and the inflammation resolves, corticosteroid and cycloplegic drops are gradually tapered and then discontinued. Most patients do not require ongoing eye drop therapy after recovery.
This depends on the specific medication and the drug class involved. In some cases, a different drug within the same class may be tolerated without problems. In other cases, cross-reactivity is possible. A retina specialist and the prescribing physician should work together to weigh the risks and benefits. Close monitoring is recommended if such a switch is made.
The timing of symptoms relative to starting a new medication is one of the strongest clues. If eye pain, redness, or blurred vision begin days to weeks after starting a new drug, a medication-related cause should be considered. However, only a thorough evaluation by a retina specialist can confirm the diagnosis. Other causes, including infections and autoimmune conditions, must be ruled out first.